ARIA Study Shows Superior Efficacy of Triumeq® for Treatment-naïve Women Living with HIV (y 3)

8. Walmsley S, Baumgarten A, Berenguer J, et al. Brief Report: Dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in Antiretroviral therapy-naive patients: Week 96 and Week 144 Results from the SINGLE randomized clinical trial. Journal of Acquired Immune Deficiency Syndromes (JAIDS). 2015;70(5):515-519. 

9. Molina J, et al. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV. 2015;2:e127-136. 

10. Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Richmond G, Buendia CB, Fourie J, Ramgopal M, Hagins D, Felizarta F, Madruga J, Reuter T, Newman T, Small CB, Lombaard J, Grinsztejn B, Dorey D, Underwood M, Griffith S, Min S, for the extended SAILING Study Team. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382(9893) :700-708. 

11. Castagna S, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the Phase III VIKING-3 study. J Infect Dis. 2014;210:354-62. 

12. Triumeq(R) (dolutegravir/abacavir/lamivudine) US prescribing information. Available at: https://www.gsksource.com/pharma/content...  

Photo:
http://photos.prnewswire.com/prnh/201602...

CONTACT: ViiV Healthcare Global/US: Media enquiries: Sébastien Desprez,+44 7920 567 707; Patricia O'Connor, +44 208 047 5982; Marc Meachem, +1 919483 8756. GSK Global Media enquiries: Simon Steele, +44 (0) 20 8047 5502;Claire Brough, +44 (0) 20 8047 5502; Catherine Hartley, +44 (0) 20 80475502; David Daley, +44 (0) 20 8047 5502